etoposide metabolite-induced topoisomerase II cleavage sites to form the breakpoint junctions may be consistent with the recently observed increased risk of treatment-related leukemia when semicontinuous or continuous oral etoposide schedules resulting in cumulative etoposide doses of more than 6 g/m2 ...